FITC Anti-CD45 antibody [MEM-28], prediluted (ab134199)
![Flow Cytometry - FITC Anti-CD45 antibody [MEM-28], prediluted (ab134199)](https://www.abcam.com/ps/products/134/ab134199/Images/ab134199-1-anti-human-CD45-fitc-flow-cyt-human-peripheral-blood.jpg "Flow Cytometry - FITC Anti-CD45 antibody [MEM-28], prediluted (ab134199)")
Key features and details
- FITC Mouse monoclonal [MEM-28] to CD45, prediluted
- Suitable for: Flow Cyt
- Reacts with: Human
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG1
Related conjugates and formulations
Overview
-
Product name
FITC Anti-CD45 antibody [MEM-28], prediluted
See all CD45 primary antibodies -
Description
FITC Mouse monoclonal [MEM-28] to CD45, prediluted -
Host species
Mouse -
Conjugation
FITC. Ex: 493nm, Em: 528nm -
Specificity
ab134199 reacts with all alternative forms of Human CD45. -
Tested applications
Suitable for: Flow Cytmore details -
Species reactivity
Reacts with: Human -
Immunogen
Tissue, cells or virus corresponding to Human CD45. Human thymocytes and T lymphocytes.
-
Positive control
- Flow Cyt: Human blood cells.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. -
Storage buffer
pH: 7.4
Preservative: 0.1% Sodium azide
Constituents: 0.2% BSA, 99% PBS -
Concentration information loading... -
Purity
Size exclusion -
Clonality
Monoclonal -
Clone number
MEM-28 -
Isotype
IgG1 -
Research areas
Associated products
-
Alternative Versions
- PE Anti-CD45 antibody [MEM-28], prediluted (ab134202)
- PerCP/Cy5.5® Anti-CD45 antibody [MEM-28] (ab157309)
- APC/Cy7® Anti-CD45 antibody [MEM-28] (ab197130)
- PE/DyLight™ 594 Anti-CD45 antibody [MEM-28] (ab223183)
- Alexa Fluor® 647 Anti-CD45 antibody [MEM-28] (ab239276)
- PE/Cy7® Anti-CD45 antibody [MEM-28] (ab239317)
- APC Anti-CD45 antibody [MEM-28] (ab28106)
- Biotin Anti-CD45 antibody [MEM-28] (ab28107)
- PerCP Anti-CD45 antibody [MEM-28] (ab65952)
- Anti-CD45 antibody [MEM-28] (ab8216)
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab134199 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Flow Cyt |
Use at an assay dependent concentration.
20 μl reagent / 100 μl of whole blood or 106 cells in a suspension. |
| Notes |
|---|
|
Flow Cyt
Use at an assay dependent concentration. 20 μl reagent / 100 μl of whole blood or 106 cells in a suspension. |
Target
-
Function
Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. -
Involvement in disease
Defects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain. -
Sequence similarities
Belongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
Contains 2 fibronectin type-III domains.
Contains 2 tyrosine-protein phosphatase domains. -
Domain
The first PTPase domain interacts with SKAP1. -
Post-translational
modificationsHeavily N- and O-glycosylated. -
Cellular localization
Membrane. Membrane raft. Colocalized with DPP4 in membrane rafts. - Information by UniProt
-
Database links
- Entrez Gene: 5788 Human
- Omim: 151460 Human
- SwissProt: P08575 Human
- Unigene: 654514 Human
-
Alternative names
- B220 antibody
- CD 45 antibody
- CD45 antibody
see all
Images
-
Flow Cytometry - FITC Anti-CD45 antibody [MEM-28], prediluted (ab134199)Flow cytometry analysis (surface staining) of human peripheral blood cells labeling CD45 with ab134199.
Datasheets and documents
-
SDS download
-
Datasheet download
References (4)
ab134199 has been referenced in 4 publications.
- Feng Y et al. Effects of human umbilical cord mesenchymal stem cells derived from exosomes on migration ability of endometrial glandular epithelial cells. Mol Med Rep 22:715-722 (2020). PubMed: 32626977
- Jin J et al. Novel SAHA-bendamustine hybrid NL-101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia. Oncol Rep 44:273-282 (2020). PubMed: 32626988
- Li X et al. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects. EBioMedicine 38:47-56 (2018). PubMed: 30472087
- Liu H et al. Human umbilical vein endothelial cell vaccine suppresses the angiogenesis of esophageal squamous cell carcinoma in a humanized mouse model. Oncol Rep 40:3006-3014 (2018). PubMed: 30132560